You are here: Welcome to the MPKB » Welcome to the MPKB » Autoimmunity Research Foundation » Timeline of the Marshall Protocol Discoveries
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:arf:timeline [02.14.2019] – [Notes and comments] sallieqhome:arf:timeline [02.14.2019] – [Timeline of the Marshall Protocol Discoveries] sallieq
Line 8: Line 8:
  
 **1981** – While a Visiting Scientist in the Dept. of Surgery at Toronto's Hospital for Sick Children, Marshall sees IBM's presentation of a few nano-seconds of life of a humulin molecule (synthetic human insulin). The presentation is one of the first //in silico// models. **1981** – While a Visiting Scientist in the Dept. of Surgery at Toronto's Hospital for Sick Children, Marshall sees IBM's presentation of a few nano-seconds of life of a humulin molecule (synthetic human insulin). The presentation is one of the first //in silico// models.
- +  
-**1984** - Marshall's PhD thesis in the [[www.library.uwa.edu.au|University of Western Australia]]  reveals the interest in mathematical modeling of human disease which would guide his research two decades later.+**1984** - Marshall's PhD thesis "Modelling and simulation in diabetes care" in the [[www.library.uwa.edu.au|University of Western Australia]]  reveals the interest in mathematical modeling of human disease which would guide his research two decades later.
  
 **1986** – Standing in a city square in Stockholm, nearly the most northerly capital in the World, Marshall's body reacts badly to sunshine. [[home:lifestyle:light:physics_of_light#latitude|He realizes]] that his sensitivity goes beyond anything medicine had envisioned, and that vitamin D must in some way be associated with chronic disease. **1986** – Standing in a city square in Stockholm, nearly the most northerly capital in the World, Marshall's body reacts badly to sunshine. [[home:lifestyle:light:physics_of_light#latitude|He realizes]] that his sensitivity goes beyond anything medicine had envisioned, and that vitamin D must in some way be associated with chronic disease.
Line 17: Line 17:
 **1999** – Marshall learns that other patients with sarcoidosis who were administered Angiotensin Receptor Blockers (ARBs) often developed a neurological reaction. Marshall starts a sabbatical in early 2001 in order to further investigate this reaction. **1999** – Marshall learns that other patients with sarcoidosis who were administered Angiotensin Receptor Blockers (ARBs) often developed a neurological reaction. Marshall starts a sabbatical in early 2001 in order to further investigate this reaction.
  
-**2001** - Marshall submits paper explaining that sarcoidosis could have a bacterial pathogenesis. Three revisions of the paper are rejected by the journal //[[http://www.sarcoidosis.it/home.html|Sarcoidosis, Vasculitis and Diffuse Lung Diseases]]// as having no potential interest for its readers. +**2001** - Marshall submits paper explaining that sarcoidosis could have a bacterial pathogenesis. Three revisions of the paper are rejected by the journal "Sarcoidosis, Vasculitis and Diffuse Lung Diseases"  as having no potential interest for its readers. 
  
 **2001 March** - The first early adopter, Elaine Emmi, begins the use of an ARB to treat her sarcoidosis. **2001 March** - The first early adopter, Elaine Emmi, begins the use of an ARB to treat her sarcoidosis.
home/arf/timeline.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.